Effect of intensive treatment with atorvastatin versus standard doses of statins on the risk of stroke. A meta-analysis from five randomized trials including 25,709 patients;Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanálisis de cinco ensayos aleatorizados con 25.709 pacientes

Revista de Neurologia

Volumn 48, Issue 11, 2009, Pages 561-565

  Fernández De Bobadilla, Jaime ^a   Moreno, R ^a   Fernandez C ^b   Martinez A ^c   Sanchez Maestre C ^c   Ezpeleta Echevarri, D ^d  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c PFIZER INC   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Atorvastatin; Intensive treatment; Ischemic heart disease; Metaanalysis; Statin; Stroke

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; FOLLOW UP; HUMAN; INCIDENCE; INTENSIVE CARE; LOW DRUG DOSE; RISK FACTOR; STROKE; CORONARY ARTERY DISEASE; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 68849132049     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4811.2009069     Document Type: Article

References (27)

1. Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998; 81: 333-335 (Pubitemid 28099310)
2. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the CARE study. Circulation 1999; 99: 216-223
3. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317-326
4. Castilla-Guerra L, Fernández-Moreno MC, López-Chozas JM, Jiménez-Hernández MD. Estatinas y enfermedad cerebrovascular: nuevas perspectivas en la prevención del ictus. Rev Neurol 2007; 44: 95-100. (Pubitemid 350277646)
5. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke 2004; 35: 2902-2909 (Pubitemid 39565192)
6. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2006; 2006; 355: 549-559
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435
8. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-2445
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504
10. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE study. J Am Coll Cardiol 2004; 44: 1772-1779
11. Stone PH, Lloyd-Jones DM, Kinlay S, Frei B, Carlson W, Rubenstein J, et al. Vascular Basis Study Group. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation 2005; 111: 1747-1755
12. Graner M, Varpula M, Kahri J, Salonen RM, Nyyssönen K, Nieminen MS, et al. Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. Am J Cardiol 2006; 97: 624-629 (Pubitemid 43255027)
13. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009 (Pubitemid 26338729)
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
15. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155: 50-55
16. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999; 99: 216-223 (Pubitemid 29056362)
17. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-1429
18. Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 2000; 10: 85-92. (Pubitemid 30107501)
19. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-445 (Pubitemid 44109954)
20. Mega JL, Braunwald E, MD Crouse JR III, Byington RP, Bond MG, Espeland MA, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-459
21. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy. Circulation 1998; 97: 1784-1790 (Pubitemid 28213621)
22. Tapia-Pérez H, Sánchez-Aguilar M, Torres-Corzo J, Rodríguez-Leyva I, Herrera-González LB. Estatinas y mecanismos de protección cerebral. Rev Neurol 2007; 45: 359-364
23. Fernández-Gómez FJ, Hernández F, Argandoña L, Galindo MF, Segura T, Jordán J. Farmacología de la neuroprotección en el ictus isquémico agudo. Rev Neurol 2008; 47: 253-260
24. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al. MIRACL Study investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106: 1690-1695
25. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767
26. Iribarren C, Reed DM, Burchfield CM, Dwyer JH. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA 1995; 273: 1926-1932
27. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, et al. SPARCL investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70: 2364-2370